Could it be that Eli Lilly's Gemzar patent expired some years ago (2010 I believe) ... and there is now a gap and room for improvement in the market.
Eli Lilly's human pharmaceutical products for oncology, included - Gemzar (Gemcitabine) and is a type of chemotherapy drug that is a treatment for a number of different cancer types.
Meanwhile, SPL's Internal DEP is progressing
https://www.starpharma.com/news/story/dep-docetaxel-and-gemcitabine-combination-trial-commences
In June 2022
https://www.starpharma.com/news/670
The company is completing final preclinical activities, including product manufacture, prior to commencing the first in-human study for this DEP® product.
Could it be that Eli Lilly's Gemzar patent expired some years...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $49.44M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.5¢ | 10.5¢ | $132.0K | 1.162M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 535926 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
12.0¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.0¢ | 12.5¢ | 10.5¢ | 991112 | ||
| Last updated 15.53pm 03/05/2024 ? | |||||
| SPL (ASX) Chart |